Asthma: is there an airway receptor barrier?

B A Hills

Clinically, asthma appears to be multifactorial as reflected by the many synonyms for the disease, but there is one feature common to all forms -- namely, the hyperresponsiveness of airways to noxious stimuli. If it were possible, one might consider introducing a physical barrier or "airway liner" (as distinct from the mucous layer), partially isolating bronchial air from the receptors which elicit these exclusion reflexes as a first line of defence. Maybe such a partial barrier is naturally present but is compromised in asthmatic subjects.

The possibility of a physical barrier was engendered some years ago upon discovery that normal tracheal or bronchial epithelium rinsed free of adhering mucus is not spontaneously wettable, but is quite hydrophobic. This was surprising because, according to classical lipid bilayer theory, the polar groups of the phospholipid molecules comprising the epithelial membrane are orientated outwards to form a hydrophilic surface. Even the intercalated protein is folded to confine any hydrophobic moieties to the central hydrophobic domain. This raises the question of what agent could be present on the airway surface to render it so hydrophobic that a droplet of saline placed on the surface would "bead up" and display an appreciable contact angle.

Surfactant

In an earlier editorial it was pointed out how such hydrophilic to hydrophobic transitions can be effected by reversible binding (adsorption) of a surfactant to the surface, as widely exploited in the industrial use of surfactants where the adsorbed layer can impart many highly desirable properties. It was also pointed out how pulmonary surfactant -- subsequently confirmed to be present in appreciable quantities in the upper airways -- possesses the same chemical groups conducive to strong adsorption, while the desirable properties include the ability of the adsorbed monolayer to act as a barrier -- for example, as "corrosion inhibitors". This has led to the discovery of the very hydrophilic nature of the gastric mucosa to which adsorbed surface active phospholipid (SAPL) offers a very effective barrier to hydrogen ions and other water soluble solutes, as reviewed recently with regard to the aetiology of peptic ulcer. It is interesting that patients with this disorder also display impaired pulmonary function for which surfactant deficiency has been offered as the common factor.

Morphology

Apart from our own studies, pulmonary surfactant has been studied only with regard to its ability to reduce the surface tension of water, the conventional model ignoring any potential function which cannot be related to the liquid-air interface. However, surfactant is highly hydrophilic and is therefore easily recognised by electron microscopy. Thus it is highly pertinent that Weibel, when summarising his many studies of the alveolar surface using conventional fixatives, describes the osmiophilic lining as "following the epithelial surface rather than the liquid-air interface", effectively confirming direct adsorption of surfactant to epithelium. A few years after our editorial proposing direct binding of surfactant, Ueda and coworkers in Japan published a series of studies in which they produced electron micrographs of superb quality clearly demonstrating the surfactant layer immediately adjacent to the epithelial surface -- not only in the alveolus but also in the upper airways. Moreover, this lining to airway epithelium appeared as oligolamellar layers almost identical to those demonstrated in the mucus-free oesophageal duct where an SAPL barrier is believed to provide mucosal protection.

The probable reason why earlier workers have not demonstrated an epithelial barrier by electron microscopy is their conventional choice of glutaraldehyde as fixative which is known to "destroy" hydrophobic surfaces. Both Ueda et al and ourselves used tannic acid for fixation, as recommended for visualising adsorbed surfactant as lamellated SAPL. Although tannic acid is capable of producing lamellated structures by phospholipid migration during fixation, such artefactual layers would only be deposited onto a hydrophobic surface and especially one already hydrophobic by virtue of a naturally adsorbed monolayer of SAPL which, incidentally, is all that is needed to provide a barrier. In any case, oligolamellar layers of SAPL have been confirmed on bronchial epithelium by epifluorescence microscopy using "hydrophobic probes" in the absence of tannic acid.

Airway receptors

The same oligolamellar layers of SAPL described above have been demonstrated adjacent to the taste receptors of the tongue leading to speculation that the function of such a lining in the airways is to "mask" receptors. A partial physical barrier separating receptors on smooth muscle and neuroepithelial cells from bronchial air might moderate the bronchoconstrictive reflex to any noxious stimuli or other airborne "triggers".
In neurophysiology the concept of “unmasking” or “uncovering” of central receptors has come into vogue as a mechanism for explaining sensitisation of a particular reflex. Typically, only 1–5% of receptors are normally “unmasked” at any one time. The question of what is normally “masking” the remaining 95–99% is seldom addressed, but there is much indirect evidence that this could be provided by adsorbed SAPL and could apply to peripheral receptors in the airways.

**Source of surfactant**

In the alveoli the source of surfactant is unequivocally lamellar bodies produced in type II pneumocytes, so it is interesting to find such bodies in neuroepithelial cells in the upper airways. Moreover, they have been observed on the epithelial surface and in the Golgi complex associated with the cell’s secretory mechanism. As the only inner-vated cells directly exposed to any noxious agent in inspired air, they appear to be secreting SAPL to mask their own receptors, thus moderating the sensitivity of the constrictive reflex.

It is also interesting to find neuroepithelial cells encircled by overwhelming Clara cells because these have the capability to scavenge and recycle surfactant. Moreover, the spatial distribution of cells observed under scanning electron microscopy indicates that, upon bronchoconstriction, the Clara cells would normally “smother” neuroepithelial cells, excluding them from contact with bronchial air and any airborne stimuli, thus providing a mechanism for limiting constriction.

**Chronic aspects**

At the risk of being grossly oversimplistic, it could be said that the immensely complex immunology of this disease and the role of allergens is reflected in the underlying inflammation of the airways which is known to persist at a reduced level in asthmatic subjects between attacks. One of the primary features of acute airway inflammation is exudation of fluid, often rich in plasma proteins. At the alveolar level such proteins are regarded as inhibitory because they deplete the surface of surfactant. As large water soluble molecules they can act as carriers for the small insoluble SAPL molecules by forming reversible phospholipoprotein bonds, thus removing surfactant as occurs in ARDS. This depletion would arise whether surfactant were located at an air-aqueous interface or adsorbed to epithelium as a barrier.

It is also easy to envisage how a non-specific blanket of SAPL, if directly adsorbed to airway receptors, might compromise their antigen recognition capabilities and their binding capability since SAPL is an excellent adhesive (release agent) when adsorbed.

**Anti-inflammatory agents**

The highly effective role of steroids in treating and preventing asthma is generally attributed to their anti-inflammatory properties. Why, therefore, are non-steroidal anti-inflammatory drugs (NSAIDs) not only ineffective, but exacerbate the disease in 10% of asthmatics? One explanation is that, just as NSAIDs are effective blood-borne “barrier breakers” in the stomach where the gastric mucosal barrier is claimed to be adsorbed SAPL, so they could denude airway receptors of essentially the same barrier. Steroids, on the other hand, have been shown to promote the secretion of SAPL in the lung, thus enhancing the receptor barrier by replenishing any deficiency in SAPL resulting from persistent inflammation or any other cause.

**Diagnostic challenges**

Diagnostic challenges in the form of histamine or methacholine can be interpreted on the basis of the surfactant model as simply testing the integrity of the SAPL barrier that separates the relevant receptors from bronchial air. However, methacholine and its isomer, acetylcholine, are particularly interesting in that their molecules possess the same terminal quaternary ammonium ion which, as a positively charged group, enables SAPL to bind to negatively charged epithelium. Thus methacholine will compete with SAPL for adsorption sites on the receptors without providing the saturated fatty acid chains needed to complete the barrier – that is, disrupting the mosaic of adsorbed SAPL molecules as discussed in molecular detail elsewhere. This is particularly pertinent because a methacholine challenge is capable of inducing acute asthma in non-asthmatic subjects, especially in children.

**Physical challenges**

Just as methacholine can compete for adsorption sites on the barrier, so other adsorption sites could compete with the receptor barrier for a limited quantity of SAPL. Competing sites could be provided in the form of mineral surfaces which avidly adsorb surfactants, especially α-quartz which can actually extract SAPL from solution in chloroform. This could be a major factor in occupational asthma.

In fixing SAPL membranes (or barriers) for electron microscopy one must be particularly careful to avoid "osmotic shock" – whether hypertonic or hypotonic – which can disrupt such structures including myelin which it resembles. Such disruption of the receptor barrier could explain bronchial hyperresponsiveness to non-isotonic aerosols. Fluid shifting rapidly into the airways with sudden exercise could also "lift off" the barrier to expose more receptors to any "triggers" in bronchial air, thus adding another to the list of explanations for sensitisation of the airways with exercise.

Any barrier deficiency of SAPL should be reflected in the adjacent mucous layer from which adsorption onto the epithelium must occur. Surfactant in physiological quantities has a major effect upon the rheology of mucus with lecithin (a crude industrial form of SAPL) being much used in the food processing industry as a "viscosity modifier". Thus SAPL deficiency could explain compaction of mucus and the viscous mucus plugs that are commonly found in the airways of asthmatic subjects.

Mucus could have an important role in stabilising the hydrophobic layer of adsorbed SAPL by reducing its interfacial energy with bronchial fluid, just as gastric mucus would appear to assume a similar role adjacent to the hydrophobic mucosal barrier.

**Chemical agents**

A potent "barrier breaker" in the stomach is bile which has a remarkable ability to remove SAPL barriers and the hydrophobicity imparted by them. Hence it is interesting that gastro-oesophageal reflux has been claimed to potentiate asthma, although this finding is controversial.

There could also be chemical attack of the barrier by enzymes such as those found in the faeces of the house dust mite, although no report on the phospholipase content could be found.

**Surfactant deficiency**

Quantitative deficiencies in surfactant have been clearly demonstrated in the upper airways of asthmatic subjects. While this is very important evidence for surfactant deficiency being viewed as a causative factor in asthma
based on the receptor barrier model, traditionalists reverse this line of reasoning to ask how asthma leads to surfactant deficiency.

This dichotomy of approach arises because, according to conventional dogma, pulmonary surfactant acts only at liquid-air interfaces to reduce the surface tension ($\gamma$) and thus the pressure difference ($\Delta P$) that causes air spaces to collapse or fluid to shift according to the Laplace equation ($\Delta P = 2\gamma/r$) where $r$ is the radius of curvature. For airways as large as bronchioles, however, $r$ is so large that $\Delta P$ is negligible whatever practical value one assumes for $\gamma$, and so the surface tension of any liquid lining is irrelevant.

Ameliorating the deficiency

If deficiency of surfactant causes airway hyperresponsiveness, protection should be afforded by administering exogenous surfactant or drugs to promote its secretion. Thus, it is particularly interesting that steroids promote surfactant secretion in the lung, as witnesses clinically by their common application antepartum to reduce the incidence of respiratory distress syndrome at birth. Although their role in asthma is traditionally attributed to their anti-inflammatory action, this explanation cannot be invoked for $\beta_2$ agonists which have been shown to have no effect on eosinophil, macrophage, lymphocyte, neutrophil, or mast cell counts. However, they invoke the immediate and dramatic release of airway surfactant witnessed in many studies reviewed by Enhorning. Moreover, unmasking might provide the answer to the "very puzzling" concerning what changes $\beta$ adrenoreceptors in asthma.

Another agent which promotes surfactant secretion in the lung is ambroxol, which is marketed as a mucolytic agent on account of the ability of SAPL to modify the rheology of mucus as outlined above. Hence it could be pertinent that this drug has also been shown to offer protection against virus-induced airway hyperresponsiveness in recent animal trials.

The prostaglandin PGE$_2$ has been shown to exert an inhibitory action on airway nerves in reducing the bronchoconstrictor response to an acetylcholine challenge. This is interesting because PGE$_2$ is intimately involved in the control of surfactant synthesis and has been found to increase its concentration on the gastric mucosa and the hydrophobicity which it imparts as a barrier, its anti-ulcer properties being well established.

The provision of more surfactant to fortify the barrier should reduce the exudation of serous fluid eroding the barrier, just as it does in distal air spaces, while the addition of exogenous SAPL to the dialysate has been shown to improve ultrafiltration of proteins during continuous ambulatory peritoneal dialysis.

Dietary aspects

Much has been written on the dietary aspects and, more recently, the possible link between the switch from butter to margarine over the last decade – which has coincided with a tenfold increase in childhood asthma over this period – as unsaturated phospholipids are less surface active. It is interesting that the incidence of peptic ulcer and osteoarthritis have followed the same trend because both are diseases in which SAPL could have major roles as either a barrier or load-bearing joint lubricant. The lower incidence of asthma claimed with higher fish oil consumption is also interesting because these lipids tend to be more saturated.

Exogenous surfactant

Direct administration of surfactant to the upper airways could be the modality of choice since it avoids the side effects of drugs, simply returning to the airways a substance that is normally present. Preliminary results from a pilot study in Japan as well as a large clinical trial in Sydney in which Exosurf is administered to asthmatic subjects have revealed appreciable amelioration of bronchoconstriction, assessed by lung function tests, and this success is continuing. Exosurf is a form of SAPL designed to spread rapidly over a liquid-air interface and has been successful in treating neonates with respiratory distress syndrome.

Conclusion

The concept of a partial barrier of surfactant separating bronchial air from the receptors capable of eliciting bronchoconstriction offers a novel physical model for asthma which complements the traditional emphasis on the immunological/allergen aspects and the whole cell biology of this disease.


Asthma: is there an airway receptor barrier?

B. A. Hills

Thorax 1996 51: 773-776
doi: 10.1136/thx.51.8.773

Updated information and services can be found at:
http:// thorax.bmj.com/content/51/8/773.citation

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http:// group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http:// journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http:// group.bmj.com/subscribe/